Drugs / SUVN-D4010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02575482 | Jul 2015 → Feb 2016 | cognitive disorder | Suven Life Sciences Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03031574 Comparator | Jan → Aug 2017 | cognitive disorder | Suven Life Sciences Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUVN-D4010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03031574 ↗ |
| Action | Activate | “SUVN-D4010 is a novel, potent, highly selective 5-HT4 partial agonist intended for the treatment of cognitive disorders.” PMID 33788154 ↗ Mar 2021 |
| Modality | Small molecule | — CHEMBL4297327 ↗ |
| Route | Oral | “SUVN-D4010 administered orally once a day to healthy male subjects.” NCT02575482 ↗ |